A somatic mutation signature predicts the best overall response to anti-programmed cell death protein-1 treatment in epidermal growth factor receptor/anaplastic lymphoma kinase-negative non-squamous non-small cell lung cancer

HIGHLIGHTS

• who: Jie Peng from the Institute (DFCI) with metastatic NSCLC treated with Affiliated Hospital of Guizhou Medical University approved ourUnited States have published the Article: A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer, in the Journal: (JOURNAL)
• how: In this study a three-step approach was used to develop and validate the somatic mutation signature (SMS) in advanced NSCLC patients undergoing immunotherapy. The SMS model was analyzed in multivariate analyses . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.